The net profit of MMCB (Gemabank) for 2023 according to RAS increased by 28.1% and amounted to 125.78 million rubles. Revenue increased by 11.3% to RUB 283.512 million. EBITDA amounted to RUB 158.595 million (55.9% of revenue). This is stated in the company's message.
The International Medical Center for the Processing and Cryopreservation of Biomaterials (MMCB (Gemabank)) is a biotechnology company, part of the Artgen Biotech group of companies, engaged in the personal storage of biomaterials, primarily hematopoietic stem cells, and the development of gene therapy drugs for the treatment of diseases of the blood and immune system.
